Researchers Have Found New Trasylol Risks

Patients Administered Trasylol May Face an Increased Risk of Kidney Failure, Heart Attack, and Death

For sometime now, researchers have been concerned that aprotinin, which is manufactured by Bayer AG and sold under the brand name Trasylol, may raise the risk of kidney failure, heart attacks, and strokes in patients who have been prescribed the drug. Trasylol is marketed for use on patients undergoing heart surgery as a means of stemming off excess bleeding. Trasylol was approved by the FDA in 1993.

New Jersey and New York defective drug lawyers at Levy Phillips & Konigsberg, LLP, warn that researchers have found new Trasylol risks. In an article entitled, “Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery,” which was published in the February 7, 2007, edition of the Journal of the American Medical Association, researchers assert that Trasylol may raise patients’ risk of dieing, within five years after the drug has been administered, by almost fifty percent. Indeed, doctors believe that replacing Trasylol with other, cheaper medications might prevent, in the next five years, as many as 10,000 aprotinin-related deaths across the world.

Bayer contested the findings of these possible Trasylol risks by stating that Trasylol is often used in complex surgeries and that the study published in the Journal of the American Medical Association did not take into account the complexity of such procedures.

Researchers conducting this study on Trysylol risks tracked 3,876 patients, who underwent heart bypass surgery, at 62 medical facilities, in 16 different nations. Over a fiver year period, they observed that 12.7 percent of patients who received other anti-bleeding drugs died in comparison to 20.8 percent of patients who passed away after taking Trasylol.

If you or any member of your family have been prescribed Trasylol and have suffered from adverse effects, you may be entitled to compensation. New Jersey and New York defective drug lawyers at Levy Phillips & Konigsberg, LLP, offers experienced representation for victims, and their families, who have suffered because of dangerous pharmaceuticals.

For further information on Trasylol risks, aprotinin-related deaths and harmful drug litigation contact Alan J. Konigsberg at (212) 605-6200.